New licensee for Stem Cell Sciences' IRES technology
This article was originally published in Scrip
Executive Summary
Stem Cell Sciences(SCS) has licensed its internal ribosome entry site (IRES) technology to an undisclosed top 20 pharmaceutical company. The deal follows a similar agreement that SCS signed in November, again with an undisclosed company, to license the IRES technology in return for $750,000 over six years as well as royalties (Scrip Online, November 24th, 2008). The value of the latest deal has not been revealed. Dr Alistair Riddell, SCS's CEO, said that he expected the company to make similar deals in the following months.